Pancreatic Cancer Screening

Gastroenterology Clinics of North America

Volumn 41, Issue 1, 2012, Pages 143-157

  Shin, Eun Ji ^a   Canto, Marcia Irene ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic predisposition; Pancreatic cancer; Screening; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN 1;

ASPIRATION BIOPSY; AUTOSOMAL DOMINANT DISORDER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; DIAGNOSTIC VALUE; ENDOSCOPIC ECHOGRAPHY; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL BREAST OVARIAN CANCER SYNDROME; FAMILIAL CANCER; GENE MUTATION; GENETIC PREDISPOSITION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS JUICE; PANCREATIC INTRAEPITHELIAL NEOPLASIA; PANCREATITIS; PENETRANCE; PEUTZ JEGHERS SYNDROME; REVIEW; SENSITIVITY AND SPECIFICITY;

EARLY DETECTION OF CANCER; HUMANS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857090212     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2011.12.001     Document Type: Review

References (131)

1. Cancer facts and figures 2011 American Cancer Society, Accessed September 1, 2011. http://www.cancer.org/acs/groups/content/epidemiologysurveilance/documents/document/acspc-029771.pdf.
2. Lynch H.T., Smyrk T., Kern S.E., et al. Familial pancreatic cancer: a review. Semin Oncol 1996, 23:251-275.
3. Brand R.E., Lynch H.T. Hereditary pancreatic adenocarcinoma: a clinical perspective. Med Clin North Am 2000, 84:665-675.
4. Klein A.P., Hruban R.H., Brune K.A., et al. Familial pancreatic cancer. Cancer J 2001, 7:266-273.
5. Lynch H.T., Krush A.J., Larsen A.L. Heredity and multiple primary malignant neoplasms: six cancer families. Am J Med Sci 1967, 254:322-329.
6. Brune K.A., Lau B., Palmisano E., et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 2010, 102:119-126.
7. Jones S., Hruban R.H., Kamiyama M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217.
8. Klein A.P., Brune K.A., Petersen G.M., et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64:2634-2638.
9. Slater E.P., Langer P., Niemczyk E., et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010, 78:490-494.
10. Klein A.P., Beaty T.H., Bailey-Wilson J.E., et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002, 23:133-149.
11. Banke M.G., Mulvihill J.J., Aston C.E. Inheritance of pancreatic cancer in pancreatic cancer-prone families. Med Clin North Am 2000, 84:677-690. x-xi.
12. Rulyak S.J., Lowenfels A.B., Maisonneuve P., et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003, 124:1292-1299.
13. Rieder H., Sina-Frey M., Ziegler A., et al. German national case collection of familial pancreatic cancer-clinical-genetic analysis of the first 21 families. Onkologie 2002, 25:262-266.
14. Pogue-Geile K.L., Chen R., Bronner M.P., et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006, 3:e516.
15. Zogopoulos G., Rothenmund H., Eppel A., et al. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet 2007, 121:635-637.
16. Slater E., Amrillaeva V., Fendrich V., et al. Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med 2007, 4:e164.
17. Klein A.P., de Andrade M., Hruban R.H., et al. Linkage analysis of chromosome 4 in families with familial pancreatic cancer. Cancer Biol Ther 2007, 6:320-323.
18. Earl J., Yan L., Vitone L.J., et al. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:1948-1955.
19. Salaria S.N., Illei P., Sharma R., et al. Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol Ther 2007, 6:324-328.
20. Murphy K.M., Brune K.A., Griffin C., et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62:3789-3793.
21. Hahn S.A., Greenhalf B., Ellis I., et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003, 95:214-221.
22. Couch F.J., Johnson M.R., Rabe K.G., et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:342-346.
23. Greer JB, Brand RE. New developments in pancreatic cancer. Curr Gastroenterol Rep; 13:131-9.
24. Stadler Z.K., Salo-Mullen E., Sabbaghian N., et al. Germline PALB2 mutation analysis in breast-pancreas cancer families. J Med Genet 2011, 48:523-525.
25. Hofstatter E.W., Domchek S.M., Miron A., et al. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 2011, 10:225-231.
26. Grover S., Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010, 139:1076-1080. 1080 e1-2.
27. Lowenfels A.B., Maisonneuve P., Whitcomb D.C. Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am 2000, 84:565-573.
28. Teich N., Nemoda Z., Kohler H., et al. Gene conversion between functional trypsinogen genes PRSS1 and PRSS2 associated with chronic pancreatitis in a six-year-old girl. Hum Mutat 2005, 25:343-347.
29. Teich N., Rosendahl J., Toth M., et al. Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum Mutat 2006, 27:721-730.
30. Sahin-Toth M., Toth M. Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem Biophys Res Commun 2000, 278:286-289.
31. Whitcomb D.C., Ulrich C.D. Hereditary pancreatitis: new insights, new directions. Baillieres Best Pract Res Clin Gastroenterol 1999, 13:253-263.
32. Lowenfels A.B., Maisonneuve P., DiMagno E.P., et al. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997, 89:442-446. International Hereditary Pancreatitis Study Group.
33. Howes N., Lerch M.M., Greenhalf W., et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004, 2:252-261.
34. Lowenfels A.B., Maisonneuve P., Whitcomb D.C., et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001, 286:169-170.
35. Latchford A., Greenhalf W., Vitone L.J., et al. Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg 2006, 93:1446-1455.
36. Gruber S.B., Entius M.M., Petersen G.M., et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res 1998, 58:5267-5270.
37. Giardiello F.M., Brensinger J.D., Tersmette A.C., et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119:1447-1453.
38. Lynch H.T., Fusaro R.M., Sandberg A.A., et al. Chromosome instability and the FAMMM syndrome. Cancer Genet Cytogenet 1993, 71:27-39.
39. Haluska F.G., Hodi F.S. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998, 16:670-682.
40. Soufir N., Avril M.F., Chompret A., et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 1998, 7:209-216. The French Familial Melanoma Study Group.
41. Lynch H.T., Brand R.E., Hogg D., et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002, 94:84-96.
42. Lynch H.T., Fusaro R.M., Lynch J.F., et al. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008, 7:103-112.
43. Goldstein A.M., Fraser M.C., Struewing J.P., et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995, 333:970-974.
44. Geary J., Sasieni P., Houlston R., et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 2008, 7:163-172.
45. Kastrinos F., Mukherjee B., Tayob N., et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009, 302:1790-1795.
46. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91:1310-1316. The Breast Cancer Linkage Consortium.
47. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002, 94:1365-1372.
48. Thompson D., Easton D.F. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002, 94:1358-1365.
49. Lal G., Liu G., Schmocker B., et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000, 60:409-416.
50. van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J., et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005, 42:711-719.
51. Goggins M., Schutte M., Lu J., et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-5364.
52. Struewing J.P., Abeliovich D., Peretz T., et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995, 11:198-200.
53. Hartge P., Struewing J.P., Wacholder S., et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 1999, 64:963-970.
54. Ozcelik H., Schmocker B., Di Nicola N., et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997, 16:17-18.
55. Roa B.B., Boyd A.A., Volcik K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14:185-187.
56. Steinberg W.M., Barkin J.S., Bradley E.L., et al. Should patients with a strong family history of pancreatic cancer be screened on a periodic basis for cancer of the pancreas?. Pancreas 2009, 38:e137-e150.
57. Canto M.I. Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin Oncol 2007, 34:295-302.
58. Vitone L.J., Greenhalf W., McFaul C.D., et al. The inherited genetics of pancreatic cancer and prospects for secondary screening. Best Pract Res Clin Gastroenterol 2006, 20:253-283.
59. Bunger S., Laubert T., Roblick U.J., et al. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 2011, 137:375-389.
60. Brentnall T.A., Bronner M.P., Byrd D.R., et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999, 131:247-255.
61. Goggins M. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 2007, 34:303-310.
62. Ritts R.E., Pitt H.A. CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am 1998, 7:93-101.
63. Safi F., Schlosser W., Falkenreck S., et al. CA 19-9 serum course and prognosis of pancreatic cancer. Int J Pancreatol 1996, 20:155-161.
64. Tian F., Appert H.E., Myles J., et al. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992, 215:350-355.
65. Mann D.V., Edwards R., Ho S., et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000, 26:474-479.
66. Rosty C., Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002, 16:37-52.
67. DiMagno E.P., Reber H.A., Tempero M.A. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999, 117:1464-1484. American Gastroenterological Association.
68. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990, 85:350-355.
69. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999, 10(Suppl 4):145-149.
70. Zubarik R., Gordon S.R., Lidofsky S.D., et al. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc 2011, 74:87-95.
71. Futakawa N., Kimura W., Yamagata S., et al. Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg 2000, 7:63-71.
72. Basso D., Fabris C., Del Favero G., et al. Serum carcinoembryonic antigen in the differential diagnosis of pancreatic cancer: influence of tumour spread, liver impairment, and age. Dis Markers 1988, 6:203-207.
73. Chevinsky A.H. CEA in tumors of other than colorectal origin. Semin Surg Oncol 1991, 7:162-166.
74. Ona F.V., Zamcheck N., Dhar P., et al. Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 1973, 31:324-327.
75. Sharma C., Eltawil K.M., Renfrew P.D., et al. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011, 17:867-897.
76. Duraker N., Hot S., Polat Y., et al. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007, 95:142-147.
77. Ehmann M., Felix K., Hartmann D., et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007, 34:205-214.
78. Gansauge F., Gansauge S., Parker N., et al. CAM 17.1-a new diagnostic marker in pancreatic cancer. Br J Cancer 1996, 74:1997-2002.
79. Groblewska M., Mroczko B., Wereszczynska-Siemiatkowska U., et al. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med 2007, 45:30-34.
80. Liao W.C., Wu M.S., Wang H.P., et al. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 2009, 38:422-426.
81. Mroczko B., Lukaszewicz-Zajac M., Wereszczynska-Siemiatkowska U., et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009, 38:613-618.
82. Gold D.V., Modrak D.E., Ying Z., et al. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006, 24:252-258.
83. Gold D.V., Goggins M., Modrak D.E., et al. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010, 19:2786-2794.
84. Gold D.V., Karanjawala Z., Modrak D.E., et al. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007, 13:7380-7387.
85. Friess H., Buchler M., Auerbach B., et al. CA 494-a new tumor marker for the diagnosis of pancreatic cancer. Int J Cancer 1993, 53:759-763.
86. Simeone D.M., Ji B., Banerjee M., et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007, 34:436-443.
87. Bouvet M., Nardin S.R., Burton D.W., et al. Parathyroid hormone-related protein as a novel tumor marker in pancreatic adenocarcinoma. Pancreas 2002, 24:284-290.
88. Kumar Y., Gurusamy K., Pamecha V., et al. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas 2007, 35:114-119.
89. Louhimo J., Alfthan H., Stenman U.H., et al. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 2004, 66:126-131.
90. Watanabe H., Ha A., Hu Y.X., et al. K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma. Cancer 1999, 86:1441-1448.
91. Caldas C., Hahn S.A., da Costa L.T., et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-32.
92. Trumper L., Menges M., Daus H., et al. Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: a multicenter prospective trial. J Clin Oncol 2002, 20:4331-4337.
93. Berger D.H., Chang H., Wood M., et al. Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer 1999, 85:326-332.
94. Kalthoff H., Schmiegel W., Roeder C., et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993, 8:289-298.
95. Schutte M., Hruban R.H., Geradts J., et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997, 57:3126-3130.
96. Tada M., Komatsu Y., Kawabe T., et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002, 97:2263-2270.
97. Sturm P.D., Hruban R.H., Ramsoekh T.B., et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998, 186:247-253.
98. Sato N., Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 2006, 13:286-295.
99. Sato N., Ueki T., Fukushima N., et al. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002, 123:365-372.
100. Sato N., Fukushima N., Chang R., et al. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 2006, 130:548-565.
101. Fukushima N., Walter K.M., Uek T., et al. Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2003, 2:78-83.
102. Ueki T., Walter K.M., Skinner H., et al. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene 2002, 21:2114-2117.
103. Matsubayashi H., Sato N., Fukushima N., et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 2003, 9:1446-1452.
104. Fukushima N., Sato N., Sahin F., et al. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 2003, 89:338-343.
105. Sato N., Fukushima N., Maehara N., et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003, 22:5021-5030.
106. Jansen M., Fukushima N., Rosty C., et al. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther 2002, 1:293-296.
107. Sato N., Fukushima N., Maitra A., et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003, 63:3735-3742.
108. Matsubayashi H., Canto M., Sato N., et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006, 66:1208-1217.
109. Polyak K., Li Y., Zhu H., et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998, 20:291-293.
110. Jones J.B., Song J.J., Hempen P.M., et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res 2001, 61:1299-1304.
111. Maitra A., Cohen Y., Gillespie S.E., et al. The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res 2004, 14:812-819.
112. Fliss M.S., Usadel H., Caballero O.L., et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000, 287:2017-2019.
113. Sanchez-Cespedes M., Parrella P., Nomoto S., et al. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res 2001, 61:7015-7019.
114. Kuroki-Suzuki S., Kuroki Y., Nasu K., et al. Pancreatic cancer screening employing noncontrast magnetic resonance imaging combined with ultrasonography. Jpn J Radiol 2011, 29:265-271.
115. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006, 4:766-781. [quiz 665].
116. Canto M.I., Goggins M., Yeo C.J., et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004, 2:606-621.
117. Ikeda M., Sato T., Morozumi A., et al. Morphologic changes in the pancreas detected by screening ultrasonography in a mass survey, with special reference to main duct dilatation, cyst formation, and calcification. Pancreas 1994, 9:508-512.
118. Medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999, 117:1463-1484. American Gastroenterological Association.
119. Canto M.I. Screening and surveillance approaches in familial pancreatic cancer. Gastrointest Endosc Clin N Am 2008, 18:535-553. x.
120. Bronstein Y.L., Loyer E.M., Kaur H., et al. Detection of small pancreatic tumors with multiphasic helical CT. Am J Roentgenol 2004, 182:619-623.
121. Vargas R., Nino-Murcia M., Trueblood W., et al. MDCT in pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. Am J Roentgenol 2004, 182:419-425.
122. Diehl S.J., Lehmann K.J., Sadick M., et al. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998, 206:373-378.
123. Lu D.S., Reber H.A., Krasny R.M., et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. Am J Roentgenol 1997, 168:1439-1443.
124. Canto M.I., Schulick R.D., Goggins M.G., et al. Preoperative detection of familial pancreatic neoplasms by endoscopic ultrasonography (EUS), multidetector computed tomography (CT), and/or magnetic resonance cholangiopancreatography (MRCP). Gastrointest Endosc 2008, 67:AB225.
125. Vasen H.F., Wasser M., van Mil A., et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 2011, 140:850-856.
126. Poley J.W., Kluijt I., Gouma D.J., et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009, 104:2175-2181.
127. Brentnall T.A. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am 2000, 84:707-718.
128. Tanaka M., Chari S., Adsay V., et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006, 6:17-32.
129. Emerson R.E., Randolph M.L., Cramer H.M. Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of intraductal papillary mucinous neoplasm of the pancreas is highly predictive of pancreatic neoplasia. Diagn Cytopathol 2006, 34:457-462.
130. Ludwig E., Olson S.H., Bayuga S., et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011, 106:946-954.
131. Verna E.C., Hwang C., Stevens P.D., et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010, 16:5028-5037.